U.S. Building Stock News

NasdaqGS:EXE
NasdaqGS:EXEOil and Gas

Is Expand Energy (EXE) Pricing Reflect Long Term Cash Flow Forecasts After Recent Reassessment?

If you are wondering whether Expand Energy is still worth your attention at around US$102.75, the key question is how that price stacks up against the company’s underlying value. The stock has been relatively steady in the short term, with returns of 0.5% over the last 7 days and 2.9% over the last 30 days, while year to date it is down 6.4% and the 1 year return is a marginal 0.4%, set against a 46.1% 3 year return and a 195.9% 5 year return. Recent news coverage around Expand Energy has...
NYSE:NFG
NYSE:NFGGas Utilities

Is It Too Late To Consider National Fuel Gas (NFG) After Its Strong 5 Year Run?

If you are wondering whether National Fuel Gas is still reasonably priced after its run, this breakdown will help you work out what you are really paying for today. The stock most recently closed at US$87.17, with reported returns of 2.7% over 7 days, 7.3% over 30 days, 6.2% year to date, 22.3% over 1 year, 70.9% over 3 years and 123.3% over 5 years. Recent coverage has focused on how National Fuel Gas fits into the wider US utilities sector and how investors are thinking about regulated...
NYSE:SNOW
NYSE:SNOWIT

Snowflake OpenAI Deal Puts AI Growth Story Against Weak Share Momentum

Snowflake (NYSE:SNOW) has agreed a $200 million partnership with OpenAI to bring OpenAI models into its Cortex AI platform. The company launched Cortex Code, a coding agent aimed at helping developers build on Snowflake more efficiently. Snowflake also announced new enterprise AI deployments with clients including United Rentals and Wolfspeed. For investors watching NYSE:SNOW, this AI push lands at a time when the shares trade around $177.1 and recent returns have been mixed. The stock...
NYSE:CBZ
NYSE:CBZProfessional Services

Is CBIZ’s (CBZ) New Buyback Plan Reframing Its Capital Allocation Strategy or Simply Staying the Course?

In February 2026, CBIZ, Inc. announced a new share repurchase program authorizing the buyback of up to 5,000,000 shares through March 31, 2027, funded by operating cash flow and its credit facility following the expiration of its prior plan. This renewed commitment to returning capital highlights management’s confidence in CBIZ’s cash generation and balance sheet flexibility even as it continues to fund growth initiatives. We’ll now examine how this newly authorized, debt-supported...
NYSE:JBL
NYSE:JBLElectronic

Is Jabil (JBL) Still Attractive After Multi‑Year Surge And Fresh DCF Valuation?

If you are wondering whether Jabil's current share price reflects its underlying value, this article will walk you through what the numbers actually say. Jabil shares last closed at US$257.40, with returns of a 0.6% decline over 7 days, 2.4% over 30 days, 7.1% year to date, 51.7% over 1 year and a very large gain over 5 years. Recent headlines around Jabil have focused on its position as a key manufacturing partner for large electronics and industrial customers, as well as ongoing portfolio...
NYSE:BANC
NYSE:BANCBanks

A Look At Banc Of California (BANC) Valuation As Recent Returns Draw Investor Attention

Why Banc of California is on investors’ radar today Banc of California (BANC) is drawing attention after recent share price moves, with the stock last closing at $20.10. Investors are weighing this level against the bank’s current earnings profile and valuation signals. See our latest analysis for Banc of California. At the current share price of $20.10, Banc of California’s recent 18.93% 3 month share price return and 29.49% 1 year total shareholder return suggest momentum has improved...
NasdaqGM:OCUL
NasdaqGM:OCULPharmaceuticals

Is It Time To Reassess Ocular Therapeutix (OCUL) After The Recent Share Price Slump

If you are trying to figure out whether Ocular Therapeutix at around US$6.99 still offers value or has run its course, you are in the right place. The stock has recently been volatile, with a 22.6% decline over the last 7 days, a 38.0% decline over 30 days and a 40.9% decline year to date, while the 3 year return sits at 21.8%. Recent headlines around Ocular Therapeutix have focused on its position in ophthalmology and how its pipeline and products could shape future prospects. This helps...
NasdaqGM:ATRC
NasdaqGM:ATRCMedical Equipment

Why AtriCure (ATRC) Is Down 12.9% After Issuing 2026 Profitability Guidance And Revenue Outlook

AtriCure, Inc. recently reported its fourth quarter and full-year 2025 results, with quarterly revenue of US$140.5 million, a swing to net income of US$1.76 million, and substantially reduced full-year losses alongside 2025 revenue of US$534.53 million. Management also issued 2026 guidance calling for US$600 million to US$610 million in revenue and positive net income, while highlighting progress in key clinical programs and new product launches that could influence the company’s market...
NYSE:BKD
NYSE:BKDHealthcare

A Look At Brookdale Senior Living’s Valuation As Upcoming Earnings Highlight Revenue And Loss Concerns

Brookdale Senior Living (BKD) is back in focus as it prepares to release its Q4 2025 earnings after the market closes today, with investors watching revenue trends and loss expectations closely. See our latest analysis for Brookdale Senior Living. The share price has been strong heading into the release, with a 30 day share price return of 36.39% and a year to date share price return of 53.51%. At the same time, the 1 year total shareholder return of 213.96% and 3 year total shareholder...
NasdaqGM:INOD
NasdaqGM:INODProfessional Services

Is Innodata (INOD) Pricing In Too Much Optimism After Recent Share Price Weakness

If you are wondering whether Innodata's recent share price pulls you toward a bargain or a value trap, this article will walk through what the current market price might be saying about the stock. The share price closed at US$43.02, with returns of a 9.5% decline over 7 days, a 30.1% decline over 30 days and an 18.8% decline year to date. Over the past 3 years and 5 years, the returns are very large compared to the starting point. Over the past year, Innodata has also recorded a 25.9%...
NYSE:CTVA
NYSE:CTVAChemicals

Corteva (CTVA) Valuation Check After Resurrect Bio Funding And Recent Share Price Momentum

Corteva (CTVA) is drawing fresh attention after leading Resurrect Bio’s US$8.1 million Series A round through its Corteva Catalyst platform. The move is aimed at supporting new crop protection traits and potential commercial partnerships. See our latest analysis for Corteva. Alongside the Resurrect Bio investment and a recently completed US$569.98 million share buyback, Corteva’s 30 day share price return of 8.49% and 90 day share price return of 16.81% suggest momentum has been building,...
NasdaqGS:PLTR
NasdaqGS:PLTRSoftware

Palantir Moves Headquarters To Miami As Valuation And Growth Scrutinized

Palantir Technologies (NasdaqGS:PLTR) is relocating its headquarters from Denver to Miami. The move places Palantir among a group of technology firms expanding operations in Florida. The relocation reflects management’s growing presence in the Miami area and interest in the state’s business environment. Palantir focuses on data analytics and AI platforms used by government agencies and commercial clients, so its corporate moves tend to draw attention from both investors and policymakers...
NYSE:KNSL
NYSE:KNSLInsurance

Does Kinsale Capital Group's (KNSL) Higher Earnings And New Dividend Clarify Its Capital Allocation Priorities?

Kinsale Capital Group, Inc. recently reported past fourth quarter and full-year 2025 results, with revenue rising to US$483.27 million and US$1.87 billion respectively, alongside higher net income and earnings per share year over year. The company’s strong profitability was accompanied by a new US$0.25 per-share dividend declaration and a board transition that reduces the director count from ten to nine without reported governance disputes. We’ll now explore how Kinsale’s stronger earnings...
NYSE:PFE
NYSE:PFEPharmaceuticals

Pfizer’s BRAFTOVI Data Adds New Dimension To Oncology Growth Story

Pfizer reported positive pivotal results from its BREAKWATER trial for the BRAFTOVI based regimen in first line treatment of BRAF V600E mutant metastatic colorectal cancer. The data showed significant progression free survival improvements, and Pfizer is moving the regimen through the approval process as a potential new therapy option. For investors watching NYSE:PFE, this update adds a fresh data point to the story at a time when the stock trades around $27.37. Shares are up 6.7% over the...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

Teva’s Duvakitug Data Puts Ulcerative Colitis And Crohn’s Bet In Focus

Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi reported positive long term results from the RELIEVE UCCD extension study of duvakitug in ulcerative colitis and Crohn’s disease. The TL1A antibody maintained efficacy and safety over 44 weeks in patients with inflammatory bowel disease. The partners plan to advance duvakitug into phase III trials, targeting a potential best in class therapy in this treatment area. For you as an investor following NYSE:TEVA, this update sits at the...
NasdaqGS:AFRM
NasdaqGS:AFRMDiversified Financial

Is It Too Late To Reconsider Affirm Holdings (AFRM) After Recent Share Price Volatility

Wondering whether Affirm Holdings at around US$51.60 still lines up with the story you have in mind, or if the current price is getting ahead of itself or lagging behind the fundamentals. The stock has recently been volatile, with a 13.5% decline over the last 7 days, a 31.0% decline over the last 30 days, and a 30.3% decline year to date, even though the 3 year return is very large at about 3x and the 1 year return sits at a 36.3% decline. Recent headlines around Affirm have focused on its...
NYSE:BWA
NYSE:BWAAuto Components

Assessing BorgWarner (BWA) Valuation After Analyst Upgrades And New EV Supply Agreements

Why recent analyst upgrades are putting BorgWarner (BWA) on investors’ radar Recent analyst upgrades for BorgWarner (BWA), backed by fresh supply deals in electric and hybrid systems, have pushed the stock into focus for investors watching the auto parts shift toward electrified powertrains. See our latest analysis for BorgWarner. BorgWarner’s recent contracts in hybrid and electric systems, a fresh Master Supply Agreement for turbine generators tied to AI data centers, an active buyback...